drugset / Trial / NCT05247684
AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
RandomizedParallel-groupOpen-labelTreatment
Summary
AK112, alone or in combination with chemotherapy for the neoadjuvant/adjuvant treatment of resectable NSCLC
Timeline
- Start
- 2022-02-20
- Primary completion
- 2025-08-18
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Cisplatin | Other / unclassified | — | Intravenous |
| Subject | Ivonescimab | Monoclonal antibody | — | Intravenous |
| Subject | Paclitaxel | Small molecule | — | Intravenous |